COMMUNIQUÉS West-GlobeNewswire

Operational Update

01/11/2018 - 13:00

Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patients AIPAC Phase IIb recruitment reaches 155 patients or more than 68% of total patients [...]

Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th

01/11/2018 - 13:00

SANTA MONICA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]

Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa

01/11/2018 - 13:00

WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]

Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach, FL

01/11/2018 - 13:00

MINNEAPOLIS, Minn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced today that [...]

Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen™ in United States and Canada

01/11/2018 - 13:00

CHARLESTON, S.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announces that it was advised yesterday that Strongbridge BioPharma Plc has signed an agreement with Novo Nordisk A/S [...]

TRHC Praises Signing of SUPPORT for Patients and Communities Act

01/11/2018 - 13:00

MOORESTOWN, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, applauds the signing into law of the [...]

Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update

01/11/2018 - 13:00

Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings Published Data from Phase 1 Study of Marzeptacog Alfa (Activated) in the Journal of [...]

MannKind Corporation Reports 2018 Third Quarter Financial Results

01/11/2018 - 13:00

Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royalties Executed research agreement for a [...]

Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019

01/11/2018 - 12:40

TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million. 2019 Medicare Part D coverage for TYMLOS increased from 44% to 64% Elacestrant Phase 3 study to target a broader patient [...]

Announcement no. 10/2018 - Annual Report 2017/18 and Corporate Responsibility Report

01/11/2018 - 12:35

Please see enclosed pdf files. Attachments Annual Report 2017-18 CR Report 2017_18

Coloplast delivers solid full-year result and 8% growth for the sixth quarter running

01/11/2018 - 12:34

Coloplast delivered 8% organic revenue growth in the fourth quarter of the 2017/18 financial year and 8% full-year organic revenue growth as well as a 31% EBIT margin. The company is guiding for ~8% organic revenue [...]

Announcement no. 9/2018 - Full-year Financial Results 2017/18

01/11/2018 - 12:31

2017/18 Announcement of full-year financial results 2017/18 (01 October 2017 - 30 September 2018) Highlights Lars Rasmussen steps down as CEO of Coloplast A/S. The Board of Directors appoints Kristian Villumsen as new [...]

Lars Rasmussen resigns his position as CEO of Coloplast A/S. The board has appointed current Executive Vice President for Coloplast Chronic Care, Kristian Villumsen, as new CEO of the company.

01/11/2018 - 12:30

After 30 years in Coloplast, 17 of them in Executive Management and 10 years as CEO, Lars Rasmussen has decided to resign his position as CEO of Coloplast A/S as of December 4 th, 2018. Succeeding Lars, who during his [...]

Announcement no. 8/2018 - Lars Rasmussen steps down as CEO of Coloplast A/S

01/11/2018 - 12:30

Announcement No. 08/2018 1 November 2018 Lars Rasmussen steps down as CEO of Coloplast A/S. The Board of Directors appoints Kristian Villumsen as new CEO of Coloplast A/S. Coloplast A/S announces today that after 30 [...]

Nephros to Report Third Quarter 2018 Financial Results on November 8th, 2018

01/11/2018 - 12:30

SOUTH ORANGE, NJ, Nov. 01, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]

Arrayit Corporation and TeleChem International Inc Celebrate 25 Years in Business

01/11/2018 - 10:30

Sunnyvale, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces that management and staff are commemorating its 25-year business anniversary. [...]

AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases

01/11/2018 - 10:01

Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseases Meeting scheduled for November 5, 2018, from 12:00pm - 2:00pm ET AC Immune's [...]

Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations

01/11/2018 - 10:00

Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc ( [...]

OV - Clinical up-date

01/11/2018 - 09:15

Clinical up-date : Oncology Venture aims for approval of LiPlaCis ® based on pivotal study in less than 200 patients Hoersholm, Denmark and Cambridge, MA, US, November 1, 2018 - Oncology Venture A/S ("OV" or "the [...]